RIVM participates in four work packages of PERISCOPE. Our prime role is to perform clinical studies, involving participants of various age groups having received different existing pertussis vaccines, or participants who were naturally infected by B. pertussis. We will also play a crucial role in providing a well characterised natural B. pertussis strain for the development of challenge models.

RIVM will engage in the following activities:
  • establish an infrastructure for the identification of biomarkers of protection, both in pre-clinical and clinical models
  • development of a roadmap for future validation
  • establish a clinical network with an ¬†integrated technology platform